Clinicopathological Features and Survival Prognosis of Subcutaneous Panniculitis-Like T-Cell Lymphoma: A Population-Based Study from the SEER Database with Supplementary Single-Center Case Validation.
[BACKGROUND] Subcutaneous panniculitis-like T cell lymphoma (SPTCL) is a rare entity which primarily involved skin and subcutaneous tissue, with clinicopathological features similar to subcutaneous pa
APA
Zhou L, Li J (2026). Clinicopathological Features and Survival Prognosis of Subcutaneous Panniculitis-Like T-Cell Lymphoma: A Population-Based Study from the SEER Database with Supplementary Single-Center Case Validation.. International journal of general medicine, 19, 567402. https://doi.org/10.2147/IJGM.S567402
MLA
Zhou L, et al.. "Clinicopathological Features and Survival Prognosis of Subcutaneous Panniculitis-Like T-Cell Lymphoma: A Population-Based Study from the SEER Database with Supplementary Single-Center Case Validation.." International journal of general medicine, vol. 19, 2026, pp. 567402.
PMID
41883463
Abstract
[BACKGROUND] Subcutaneous panniculitis-like T cell lymphoma (SPTCL) is a rare entity which primarily involved skin and subcutaneous tissue, with clinicopathological features similar to subcutaneous panniculitis. The etiology, clinical features, clinical outcomes and prognostic factors remain largely unknown.
[METHODS] To gain insight into this distinct entity, we summarized the clinicopathologic features of 8 unpublished SPTCL cases and performed a comprehensive analysis based on SEER (Surveillance, Epidemiology, and End Results) database.
[RESULTS] Clinically, subcutaneous nodules with no tenderness appeared firstly in seven patients, and cough in one patient. Hemophagocytic syndrome developed in 3 patients. The median progression-free survival (PFS) for the whole cohort was 43 months, while the median overall survival (OS) has not reached. We identified a cohort of 210 SPTCL patients between 2000 and 2020 based on SEER database. Over half of patients had B symptoms (56.2%) and present at advanced stage (55.6%). The 5-year overall survival (OS) rate was 77.6% for the whole cohort. Multivariate analysis showed that age >60 years and diagnosis before the year 2008 were important prognostic factors of OS for SPTCL.
[CONCLUSION] Our results identified the clinical characteristics, OS and prognostic factors of a large cohort of SPTCL.
[METHODS] To gain insight into this distinct entity, we summarized the clinicopathologic features of 8 unpublished SPTCL cases and performed a comprehensive analysis based on SEER (Surveillance, Epidemiology, and End Results) database.
[RESULTS] Clinically, subcutaneous nodules with no tenderness appeared firstly in seven patients, and cough in one patient. Hemophagocytic syndrome developed in 3 patients. The median progression-free survival (PFS) for the whole cohort was 43 months, while the median overall survival (OS) has not reached. We identified a cohort of 210 SPTCL patients between 2000 and 2020 based on SEER database. Over half of patients had B symptoms (56.2%) and present at advanced stage (55.6%). The 5-year overall survival (OS) rate was 77.6% for the whole cohort. Multivariate analysis showed that age >60 years and diagnosis before the year 2008 were important prognostic factors of OS for SPTCL.
[CONCLUSION] Our results identified the clinical characteristics, OS and prognostic factors of a large cohort of SPTCL.
같은 제1저자의 인용 많은 논문 (5)
- Disease Self-Monitoring Behaviors and Influencing Factors Among Family Members of Patients With Digestive Tract Cancer: A Latent Profile Analysis.
- The absence of B7-H4 inhibits PD-L1 expression by driving a methylation of PD-L1 promoter in breast cancer cells.
- Integrated multi-dataset screening to predict prognosis and identify immunotherapy gene targets in hepatocellular carcinoma patients.
- Inhibits Breast Cancer Tumor Progression by Targeting to Regulate Glycolysis.
- Multimodal hybrid mamba classification model for tumor pathological grade prediction using magnetic resonance images.